1
|
Katoh T, Tomata Y, Setoh M, Sasaki S, Takai T, Yoshitomi Y, Yukawa T, Nakagawa H, Fukumoto S, Tsukamoto T, Nakada Y. Practical application of 3-substituted-2,6-difluoropyridines in drug discovery: Facile synthesis of novel protein kinase C theta inhibitors. Bioorg Med Chem Lett 2017; 27:2497-2501. [PMID: 28400232 DOI: 10.1016/j.bmcl.2017.03.099] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Revised: 03/30/2017] [Accepted: 03/31/2017] [Indexed: 12/11/2022]
Abstract
We previously reported a facile preparation method of 3-substituted-2,6-difluoropyridines, which were easily converted to 2,3,6-trisubstituted pyridines by nucleophilic aromatic substitution with good regioselectivity and yield. In this study, we demonstrate the synthetic utility of 3-substituted-2,6-difluoropyridines in drug discovery via their application in the synthesis of various 2,3,6-trisubstituted pyridines, including macrocyclic derivatives, as novel protein kinase C theta inhibitors in a moderate to good yield. This synthetic approach is useful for the preparation of 2,3,6-trisubstituted pyridines, which are a popular scaffold for drug candidates and biologically attractive compounds.
Collapse
Affiliation(s)
- Taisuke Katoh
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
| | - Yoshihide Tomata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masaki Setoh
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Satoshi Sasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Takafumi Takai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yayoi Yoshitomi
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tomoya Yukawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hideyuki Nakagawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shoji Fukumoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tetsuya Tsukamoto
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihisa Nakada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
2
|
Facile preparation of 3-substituted-2,6-difluoropyridines: application to the synthesis of 2,3,6-trisubstituted pyridines. Tetrahedron Lett 2015. [DOI: 10.1016/j.tetlet.2015.09.057] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Tian Z, Li D, Jiang Z, Li Z. A Facile N-monoalkylation of Aminopyridines. JOURNAL OF CHEMICAL RESEARCH 2011. [DOI: 10.3184/174751911x13190991845013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The N-monoalkylation of 2- or 3-aminopyridines by a carboxylic acid and sodium borohydride afforded the corresponding alkylaminopyridine under mild conditions in good yields. N-Alkylaminopyridines are important intermediate for preparing N-containing heterocycles, such as “flytrap” aminopyridinium-based anion hosts and pharmaceuticals.
Collapse
Affiliation(s)
- Zhongzhen Tian
- Shandong Provincial Key Laboratory of Fluorine Chemistry and Chemical Materials, School of Chemistry and Chemical Engineering, University of Jinan, 106 Jiwei Road, Jinan 250022, P. R. China
| | - Dongmei Li
- Shandong Provincial Key Laboratory of Fluorine Chemistry and Chemical Materials, School of Chemistry and Chemical Engineering, University of Jinan, 106 Jiwei Road, Jinan 250022, P. R. China
| | - Zhaoxing Jiang
- Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China
| | - Zhong Li
- Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China
| |
Collapse
|
4
|
Naik P, Murumkar P, Giridhar R, Yadav MR. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists—A perspective. Bioorg Med Chem 2010; 18:8418-56. [DOI: 10.1016/j.bmc.2010.10.043] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Revised: 10/14/2010] [Accepted: 10/15/2010] [Indexed: 10/18/2022]
|
5
|
Hendricks RT, Fell JB, Blake JF, Fischer JP, Robinson JE, Spencer SR, Stengel PJ, Bernacki AL, Leveque VJ, Pogam SL, Rajyaguru S, Najera I, Josey JA, Harris JR, Swallow S. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors. Bioorg Med Chem Lett 2009; 19:3637-41. [DOI: 10.1016/j.bmcl.2009.04.119] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2009] [Revised: 04/23/2009] [Accepted: 04/24/2009] [Indexed: 12/01/2022]
|
6
|
Wang X, Zhi B, Baum J, Chen Y, Crockett R, Huang L, Eisenberg S, Ng J, Larsen R, Martinelli M, Reider P. A practical synthesis of 2-((1H-pyrrolo[2,3-b]pyridine-4-yl)methylamino)-5- fluoronicotinic acid. J Org Chem 2007; 71:4021-3. [PMID: 16674090 DOI: 10.1021/jo0602571] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A practical synthesis of a key pharmaceutical intermediate, 2-[(1H-pyrrolo[2,3-b]pyridine-4-yl)methylamino]-5-fluoronicotinic acid (1), is described. To introduce the aminomethyl moiety of 2 via a palladium-catalyzed cyanation/reduction sequence, a regioselective chlorination of 7-azaindole via the N-oxide was developed. A highly selective monodechlorination of 2,6-dichloro-5-fluoronicotinic acid was discovered to afford the nicotinic acid 3. The two building blocks 2 and 3 were then coupled to complete the preparation of 1.
Collapse
Affiliation(s)
- Xin Wang
- Chemical Process R & D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Su Q, Zhou L. QSAR modeling of AT1 receptor antagonists using ANN. J Mol Model 2006; 12:869-75. [PMID: 16541251 DOI: 10.1007/s00894-006-0105-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2005] [Accepted: 01/18/2006] [Indexed: 11/25/2022]
Abstract
Multiple linear regression (MLR) and artificial neural networks (ANN) have been used for structure-activity relationship analysis for a set of 113 AT1 receptor antagonists. The ANN model showed better performance with a 6-6-1 architecture than MLR. The results obtained from this study indicate that three descriptors, hydration energy (EH), n-octanol/water partition (LOGP), and energy of the lowest unoccupied molecular orbital (LUMO), play an important role on the activity of AT1 receptor antagonists with biphenyltetrazole structures. This information is pertinent to the further design of new AT1 receptor antagonists. 1 A plot of observed versus predicted PIC50 produced from the best nonlinear model using 6-6-1 architecture.
Collapse
Affiliation(s)
- Qing Su
- Department of Pharmaceutical Engineering, College of Chemical Engineering, Sichuan University, Chengdu, Sichuan, 610065, China.
| | | |
Collapse
|
8
|
Transformations of ortho-methoxyaryl(hetaryl)carboxamides into quinazolin-4-one and pyrido[2,3-d]pyrimidin-4-one derivatives. Russ Chem Bull 2005. [DOI: 10.1007/s11172-006-0057-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Affiliation(s)
- A Kurup
- Department of Chemistry, Pomona College, Claremont, CA 91711, USA
| | | | | | | |
Collapse
|
10
|
Attanasi OA, Colombani SM, De Crescentini L, Giorgi R, Monti S, Perrone A, Perrulli FR, Renzetti AR, Santeusanio S. Synthesis of biphenylyltetrazole derivatives of 1-aminopyrroles as angiotensin II antagonists. FARMACO (SOCIETA CHIMICA ITALIANA : 1989) 1999; 54:64-76. [PMID: 10321031 DOI: 10.1016/s0014-827x(98)00100-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Based on preliminary molecular modelling study, the synthesis of two different classes of biphenylyltetrazole derivatives of 1-aminopyrroles, as potentially active non-peptide angiotensin II (AII) antagonists, is reported. Some NH-Boc protected l-aminopyrroles were deprotected, N-acylated, N-alkylated with 5-[4'-bromomethyl-1,1'-biphenyl-2-yl]-1-triphenylmethyl-1H-tetrazo le, and then detritylated to give the first class of title compounds. Other 1-NH-Boc protected 1,2-diaminopyrroles were regioselectively subjected to the 1-alkylation with 5-[4'-bromomethyl-1,1'-biphenyl-2-yl]-1-triphenylmethyl-1H-tetrazo le, to the acylation of the amino group at 2-position of the pyrrole ring, and then to the detritylation process to yield the second class of title compounds.
Collapse
Affiliation(s)
- O A Attanasi
- Institute of Organic Chemistry, Faculty of Science, Urbino University, Italy. (O.A. Attanasi)
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Segarra V, Crespo MI, Pujol F, Beleta J, Doménech T, Miralpeix M, Palacios JM, Castro A, Martinez A. Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. Bioorg Med Chem Lett 1998; 8:505-10. [PMID: 9871607 DOI: 10.1016/s0960-894x(98)00058-4] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A 4-centre PDE4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developing PDE4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured.
Collapse
Affiliation(s)
- V Segarra
- Almirall Prodesfarma Research Center, Barcelona, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
von Geldern TW, Hoffman DJ, Kester JA, Nellans HN, Dayton BD, Calzadilla SV, Marsh KC, Hernandez L, Chiou W, Dixon DB, Wu-Wong JR, Opgenorth TJ. Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption. J Med Chem 1996; 39:982-91. [PMID: 8632421 DOI: 10.1021/jm9505932] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The oral absorption profile of a family of azole-based ET(A)-selective antagonists has been improved through a rational series of structural modifications which were suggested by analysis of the physicochemical parameter delta log P. Comparison of urea 2 with a series of well-absorbed compounds using delta log P analysis suggested that 2 has an excess capacity for forming hydrogen bonds with solvent. A series of urea modifications were explored as a means of reducing H-bonding capacity while maintaining affinity for the ET(A)-receptor. The correlation between delta log P values and absorption in an intraduodenal (id) bioavailability model was good; this strategy uncovered replacements for each of the urea NH groups which simultaneously improve both potency and drug absorption. A combination of these optimized modifications produces carbamate 16h, a highly-selective ET(A) antagonist with a potency/bioavailability profile consistent with an oral route of administration.
Collapse
Affiliation(s)
- T W von Geldern
- Aging and Degenerative Diseases Research, Pharmaceutical Products Research Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Wexler RR, Greenlee WJ, Irvin JD, Goldberg MR, Prendergast K, Smith RD, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem 1996; 39:625-56. [PMID: 8576904 DOI: 10.1021/jm9504722] [Citation(s) in RCA: 225] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- R R Wexler
- DuPont Merck Pharmaceutical Company, Wilmington, Delaware, USA
| | | | | | | | | | | | | |
Collapse
|
14
|
Hancock AA, Buckner SA, Lee JY, Brune M, Morse PA, Oheim K, Warner RB, Winn M, Zydowsky TM, De B. Receptor interactions of Abbott-81988, a highly potent, non-peptide angiotensin-II antagonist selective for type-1 receptors. JOURNAL OF RECEPTOR RESEARCH 1994; 14:229-49. [PMID: 8083867 DOI: 10.3109/10799899409066034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Abbott-81988 (A-81988) was selected from a series of related compounds as a highly potent and selective antagonist of angiotensin receptors. In the rabbit aorta, A-81988 exhibited a pA2 of 10.12 (+/- 0.08) vs. angiotensin-II, for type 1 receptors (AT1), and the antagonism appeared competitive. These results agreed with radioligand assays in which A-81988 inhibited the binding of [125I]-Sar1-Ile8-Angiotensin-II to rat liver membranes with a pKI of 9.12 (+/- 0.63). A-81988 was selective for AT1 receptors based on its lack of activity at other sites, such as aortic alpha 1 receptors. Moreover, A-81988 lacked affinity for AT2 receptors of bovine cerebellar membranes or for alpha or beta adrenergic receptors in binding assays. A-81988 lowered blood pressure significantly in vivo in renal artery-ligated rats at doses of 0.3 mg/kg administered either i.v. or p.o. The compound was rapidly and almost completely absorbed from the duodenum of anesthetized rats and demonstrated very low first-pass metabolism in the rat liver. These properties of selectivity toward and potency for antagonizing AT1 receptors, activity in lowering blood pressure in experimental animals, and favorable pharmacokinetic properties indicate that A-81988 should be a useful antihypertensive agent in man.
Collapse
Affiliation(s)
- A A Hancock
- Abbott Laboratories, Division of Cardiovascular Research, Pharmaceutical Products Division, Abbott Park, IL 60064
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
|